These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27128830)

  • 21. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study.
    Naya N; Sakai C; Okutsu D; Kiguchi R; Fujiwara M; Tsuji T; Iwanami A
    Neuropsychopharmacol Rep; 2021 Mar; 41(1):26-39. PubMed ID: 33305542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A thorough QT study of guanfacine.
    Martin P; Satin L; Kahn RS; Robinson A; Corcoran M; Purkayastha J; Youcha S; Ermer JC
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):301-16. PubMed ID: 25109412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A; Hoo-Cardiel A; Lang P
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [No Abstract]   [Full Text] [Related]  

  • 25. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
    Schneider G; Banaschewski T; Feldman BL; Gustafsson PA; Murphy B; Reynolds M; Coghill DR; Spalding WM
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
    Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
    Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
    Ota T; Yamamuro K; Okazaki K; Kishimoto T
    Drug Des Devel Ther; 2021; 15():1965-1969. PubMed ID: 34007156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M; McBurnett K; Cutler AJ; Hervás A; Bliss C; Gao J; Dirks B; Newcorn JH
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of excessive weight gain with guanfacine extended release: 9.53 kg in 4 weeks.
    Khan MA; Jain G; Soltys SM; Takahashi A
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):256-7. PubMed ID: 22537187
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.
    Roesch B; Corcoran M; Haffey M; Stevenson A; Wang P; Purkayastha J; Martin P; Ermer J
    Drugs R D; 2013 Mar; 13(1):53-61. PubMed ID: 23519656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
    Bukstein OG; Head J
    Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
    Wilens TE; McBurnett K; Turnbow J; Rugino T; White C; Youcha S
    J Atten Disord; 2017 Jan; 21(2):110-119. PubMed ID: 24071772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Connor DF; Arnsten AF; Pearson GS; Greco GF
    Expert Opin Pharmacother; 2014 Aug; 15(11):1601-10. PubMed ID: 24992513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
    Newcorn JH; Harpin V; Huss M; Lyne A; Sikirica V; Johnson M; Ramos-Quiroga JA; van Stralen J; Dutray B; Sreckovic S; Bloomfield R; Robertson B
    J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Guanfacine Extended-Release Formulation in Healthy Japanese and Caucasian Male Adults.
    Matsuo Y; Okita M; Ermer J; Wajima T
    Clin Drug Investig; 2017 Aug; 37(8):745-753. PubMed ID: 28421383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Sallee FR; Lyne A; Wigal T; McGough JJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.
    Huss M; Dirks B; Gu J; Robertson B; Newcorn JH; Ramos-Quiroga JA
    Eur Child Adolesc Psychiatry; 2018 Oct; 27(10):1283-1294. PubMed ID: 29442229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.